AM1241 Altered Morphine-Related TRPV1 Protein Changes Without a Matching mRNA Change in Rats

A tumor-bearing rat study found increased TRPV1 protein after repeated morphine without increased TRPV1 mRNA. AM1241 reduced the protein change and morphine tolerance, suggesting regulation beyond a simple transcript increase.

The model used a heat-withdrawal endpoint

Walker 256 tumor-bearing rats received repeated morphine with or without the CB2 agonist AM1241. Paw-withdrawal latency to radiant heat assessed the antinociceptive response over the regimen. This was a controlled animal pain-response measure, not patient-reported cancer pain.

Protein and transcript gave different answers

Repeated morphine increased TRPV1 protein expression in dorsal root ganglia while mRNA remained unchanged. AM1241 pretreatment reduced the protein increase, and the CB2 antagonist AM630 reversed that effect. The antagonist comparison supports CB2 involvement but does not establish precisely which protein-regulatory process was responsible.

Mechanistic plausibility is narrower than proof of mediation

Coadministration also reduced morphine tolerance. The authors proposed a relationship to TRPV1 regulation, but concurrent changes do not show that the protein effect alone accounts for the behavioral outcome. The abstract does not establish a human treatment or the effects of cannabis products.

The study demonstrates why a negative mRNA result does not necessarily mean protein abundance is unchanged. For cannabinoid–opioid evidence, tissue, receptor subtype and measurement level matter. The result should remain a preclinical mechanistic finding rather than a claim of proven clinical benefit.

Related: interpreting cannabis tolerance claims.

Research cited

Zhang M; Chi M; Zou H; Tian S; Zhang Z; Wang G. Effects of coadministration of low dose cannabinoid type 2 receptor agonist and morphine on vanilloid receptor 1 expression in a rat model of cancer pain. Molecular medicine reports (2017). doi:10.3892/mmr.2017.7479. Findings discussed from the study abstract.

Spread the love


The National Black Lawyers

top 40 lawyers

civil trial law

Lawyers of Distinction

Loading...

Recent Blog Articles

A Clomipramine Challenge Linked Withdrawal-Like Behavior and Histamine Changes in THC-Tolerant Rats

A 1985 rat experiment reported withdrawal-like behavior and regional histamine decreases after clomipramine challenge in THC-tolerant animals. The design was a pharmacological challenge, not simply observation after THC cessation. Tolerance was established before the challenge Repeated intravenous THC produced tolerance to cooling and to the acute regional histamine reductions over…

Spread the love

Read Article: A Clomipramine Challenge Linked Withdrawal-Like Behavior and Histamine Changes in THC-Tolerant Rats

A Mouse Study Found Persistent Electrical Hyperexcitability Despite Tolerance to THC Motor Effects

A 1986 mouse study reported prolonged susceptibility to electrically induced convulsions after THC, while repeated treatment produced tolerance to motor toxicity but not that excitability endpoint. Adaptation differed between visible movement effects and a later electrical challenge. The exposure was a high-dose injected protocol The experiment examined a wide high-dose…

Spread the love

Read Article: A Mouse Study Found Persistent Electrical Hyperexcitability Despite Tolerance to THC Motor Effects

Prior THC Exposure Changed Whether Environmental Familiarity Mattered in a Rat Study

A 1987 rat experiment found environmental familiarity affected THC behavior in drug-naive animals but not in animals previously exposed to THC. The finding was an interaction between two histories, not proof that context never matters. Drug and chamber exposure were separated Four groups received prior drug exposure, prior chamber exposure,…

Spread the love

Read Article: Prior THC Exposure Changed Whether Environmental Familiarity Mattered in a Rat Study

Speak with an expert today!

Contact the offices of Okorie Okorocha for professional and reliable advice which you can trust.

Call (424) 363-3347 Contact Us